Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris PHVS, a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief Financial…#zug #switzerland #pharvarisphvs #davidnassif #jd #pharvaris #berndtmodig #morganconn #hae #siogenetherapies
Source: Reuters: Health - Category: Consumer Health News Source Type: news